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Type II diabetes mellitusHuman islet amyloid polypeptide (hIAPP) forms amyloid ﬁbrils in pancreatic islets of patients with type 2
diabetes mellitus (DM2). The formation of hIAPP ﬁbrils has been shown to cause membrane damage which
most likely is responsible for the death of pancreatic islet β-cells during the pathogenesis of DM2. Previous
studies have shown that the N-terminal part of hIAPP, hIAPP1–19, plays a major role in the initial interaction
of hIAPP with lipid membranes. However, the exact role of this N-terminal part of hIAPP in causing
membrane damage is unknown. Here we investigate the structure and aggregation properties of hIAPP1–19 in
relation to membrane damage in vitro by using membranes of the zwitterionic lipid phosphatidylcholine
(PC), the anionic lipid phosphatidylserine (PS) and mixtures of these lipids to mimic membranes of islet
cells. Our data reveal that hIAPP1–19 is weakly ﬁbrillogenic in solution and not ﬁbrillogenic in the presence of
membranes, where it adopts a secondary structure that is dependent on lipid composition and stable in time.
Furthermore, hIAPP1–19 is not able to induce leakage in membranes of PC/PS or PC bilayers, indicating that
the membrane interaction of the N-terminal fragment by itself is not responsible for membrane leakage
under physiologically relevant conditions. In bilayers of the anionic lipid PS, the peptide does induce
membrane damage, but this leakage is not correlated to ﬁbril formation, as it is for mature hIAPP. Hence,
membrane permeabilization by the N-terminal fragment of hIAPP in anionic lipids is most likely an aspeciﬁc
process, occurring via a mechanism that is not relevant for hIAPP-induced membrane damage in vivo.yl sulfoxide; hIAPP, human islet
ol; LUV, large unilamellar vesicle;
POPS, 1-palmitoyl-2-oleoyl-sn-
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Amyloid formation has been implicated in a wide range of human
diseases including Alzheimer's disease, Parkinson's disease, and type 2
diabetes mellitus (DM2). DM2 is characterized histopathologically by
the presence of ﬁbrillar amyloid deposits in the pancreatic islets of
Langerhans (islet amyloid). Amyloid cytotoxicity, most likely related
to membrane damage, is thought to be an early mechanism involved
in death of insulin-producing islet β-cells in DM2 [1]. The maincomponent of islet amyloid, and the actual ﬁbril-forming molecule, is
a 37 amino acid peptide called human islet amyloid polypeptide
(hIAPP) or amylin, which is produced and secreted together with
insulin by the pancreatic islet β-cells. The normal physiological role of
hIAPP is not entirely clear, but it is believed to play a role as a hormone
in gastric emptying, suppression of food intake, and glucose
homeostasis [2–4].
It is clear from several reports that hIAPP is able to interact with
membranes [5–10]. This interaction promotes the formation of
amyloid ﬁbrils and leads to membrane damage. However, the details
of the nature of this interaction are still unknown. Recent publications
suggest that full-length hIAPP has a pronounced ability to insert into
lipid monolayers, and that it is the N-terminal part of hIAPP and not
the amyloidogenic region that mediates the insertion of the peptide
into membranes [6,7,11]. It is not clear whether the N-terminal part of
hIAPP is involved only in membrane insertion, or whether it also
directly contributes to membrane damage. Two recent studies, using
membranes composed of anionic lipids only, indicate that hIAPP1–19
induces membrane disruption to a near identical extent as full-length
1806 L. Khemtémourian et al. / Biochimica et Biophysica Acta 1798 (2010) 1805–1811hIAPP but that it does not form any ﬁbrils, even after 15 days of
incubation [12,13]. This would suggest that ﬁbrillogenesis is not
required for membrane damage. This is unexpected since many
reports have shown that amyloid-induced membrane disruption is
directly related to the propensity to form ﬁbrils, not only for hIAPP but
also for other amyloidogenic proteins, such as Aβ in Alzheimer's
disease [8,9,14–17]. Unfortunately, comparison of published results is
hampered by the use of different lipid compositions in various studies.
To gain further insight into the nature of the initial step of hIAPP-
membrane interactions, including the potential importance of lipid
composition, and to shed light on seemingly contradicting results in
the literature, we performed a biophysical study of hIAPP1–19, which
corresponds to the N-terminal part of full-length hIAPP that is
involved in the initial steps of membrane interactions [6], in lipid
bilayers of different composition. In particular, we examined the
aggregational behaviour, the effect on membrane integrity and the
structure of hIAPP1–19 in comparison with full-length hIAPP. For these
studies we used mixtures of the zwitterionic lipid phosphatidylcho-
line (PC) and the anionic lipid phosphatidylserine (PS) in a 7:3 ratio to
mimic the membranes of pancreatic islet cells [18] and we used
bilayers composed of pure PC and PS, respectively, to obtain further
insight into the importance of electrostatic interactions, and to allow
comparison with previously reported studies on the membrane
interaction of hIAPP1–19 [13].
2. Materials and methods
2.1. Materials
Full-length hIAPP with an amidated C-terminus and disulﬁde
bridge was obtained from Bachem AG (Bubendorf, Switzerland). The
fragment hIAPP1–19 was synthesised using Fmoc chemistry on a
Tentagel S RAM resin as described previously [19,20]. Linear hIAPP1–19
was dissolved in aqueous DMSO and oxidized with air to the
corresponding disulﬁde [21]. The peptide was puriﬁed by reverse
phase high-performance liquid chromatography (HPLC). Purity of
both peptides was higher than 95% as determined by analytical HPLC
and themasses of the peptides were conﬁrmedwithMALDI-TOFmass
spectrometry. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine
(POPS) were obtained from Avanti Polar Lipids (Alabaster, AL).
Thioﬂavin T (ThT) was obtained from Sigma.
2.2. Preparation of peptide samples
hIAPP and hIAPP1–19 peptides were dissolved at a concentration of
1 mM in hexaﬂuoro-2-propanol (HFIP) and incubated for at least 1 h.
Next, HFIP was evaporated with dry nitrogen gas followed by vacuum
desiccation for at least 30 min. The resulting peptide ﬁlm was then
dissolved in DMSO for electron microscopy (EM), membrane leakage
experiments and ThT assay and in phosphate buffer for the CD
experiments. For the membrane leakage experiments, the ThT assay,
and for the EM experiments we used the same concentration of DMSO
(2.5%) and hence were able to compare for the leakage experiments
and the ThT assays the shape of the curve and the lag time.
2.3. Preparation of LUVs
LUVs were prepared of POPC, POPS or POPC/POPS in a 7:3 molar
ratio. Stock solutions of POPC and POPS in chloroform at concentra-
tions of 20–30 mM were used alone or mixed in a 7:3 molar ratio in a
glass tube. The solvent was evaporated with dry nitrogen gas yielding
a lipid ﬁlm that was further dried under vacuum for at least 30 min.
Lipid ﬁlms were hydrated in 10 mM Tris–HCl, 100 mM NaCl (pH 7.4)
during at least 30 min, at a lipid concentration of 10 mM. The lipid
suspensions were subjected to 10 freeze-thaw cycles, at temperaturesof approximately−80 and 40 °C, and subsequently extruded 10 times
through0.2 μmpore sizeﬁlters (Anotop10,Whatman,Maidstone,U.K.).
The phospholipid content of lipid stock solutions and vesicle prepara-
tions was determined as inorganic phosphate according to Rouser et al.
[22]. Calcein-containing LUVs were made using the same protocol,
except for the followingadaptations. The buffer for hydrationof the lipid
ﬁlms was replaced with a buffer containing 70 mM calcein and 10 mM
Tris–HCl (pH 7.4). Free calcein was separated from the calcein-ﬁlled
LUVs using size-exclusion column chromatography (Sephadex G-50
ﬁne) and elution with 10 mM Tris–HCl, 100 mM NaCl (pH 7.4).
2.4. Thioﬂavin T assay
The kinetics of ﬁbril formation was measured using the ﬂuores-
cence intensity increase upon binding of the ﬂuorescent dye ThT to
ﬁbrils. A plate reader (Spectraﬂuor, Tecan, Salzburg, Austria) and
standard 96-well ﬂat-bottom black microtiter plates in combination
with a 430 nm excitation ﬁlter and a 535 nm emission ﬁlter were used
as described previously [14]. The ThT assay in the presence of
membranes was started via addition of 5 μL of a 0.2 mM peptide stock
solution in DMSO to 195 μL of a mixture of 10 μM ThT, LUVs (45 μM
lipids) and 10 mM Tris–HCl, 100 mM NaCl (pH 7.4). The ThT assay in
solution was performed using the same method but without the
addition of the LUVs. The microtiter plate was shaken for 9 s, directly
after addition of all components but not during the measurement.
2.5. Electron microscopy
Peptides and LUVs were incubated under the same conditions as in
the thioﬂavin T assay. Aliquots (20 μL) of this mixture were adsorbed
onto glow-discharged carbon-coated 300-mesh copper grids for
2 min. The grids were then blotted, and dried. Next, the grids were
negatively stained for 45 s on 2% uranyl acetate, and again, blotted and
dried. The gridswere examined using a Technai 12 electronmicroscope
operating at 120 kV.
2.6. Membrane leakage experiments
A plate reader and standard 96-well transparent microtiter plates
in combination with a 485 nm excitation ﬁlter and a 535 nm emission
ﬁlter were used as described previously [14]. The leakage assay was
started by adding 5 μL of a 0.2 mM peptide stock solution in DMSO to
195 μL of a mixture of calcein containing LUVs (100 μM lipid, peptide:
lipid 1:20) and 10 mM Tris–HCl, 100 mM NaCl (pH 7.4). The DMSO
concentration of all samples was matched to 2.5% (v/v). The
microtiter plate was shaken for 9 s, directly after addition of all
components and not during the measurement. The maximum leakage
at the end of eachmeasurement was determined with Triton X-100 as
reported previously [14].
2.7. CD spectroscopy
CD spectra were recorded on a Jasco 810 spectropolarimeter (Jasco
Inc., Easton, MD) over the wavelength range 190–270 nm. Measure-
ments were taken in cells with a path length of 0.1 mm at room
temperature in 10 mM phosphate buffer (pH 7.4) and in buffer
containing either POPC, POPS or POPC/POPS (7:3) LUVs. Measure-
ments were taken every 0.2 nm at a scan rate of 20 nm/min. Each
spectrum reported is the average of ﬁve scans after subtraction of the
baseline spectrum of the buffer and vesicles without peptide. Peptide
concentrations were 25 μM in buffer and 50 μM in the presence of
lipids (1:20 peptide:lipid ratio). In order to estimate the peptide
secondary structure content, an analysis of relevant CD spectra was
carried out using the CDFriend software [23] and the CDPro2 program
[24]. Both analyses gave the same results (less than 5% difference).
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3.1. hIAPP1–19 is weakly ﬁbrillogenic in solution, but not ﬁbrillogenic in
the presence of membranes
The amino acid sequences of full-length hIAPP and hIAPP1–19 are
shown in Fig. 1. We ﬁrst investigated whether hIAPP1–19 can form
amyloid ﬁbrils in the absence of membranes by using transmission
electron microscopy (TEM) and we followed the kinetics of ﬁbril
formation using the amyloid speciﬁc thioﬂavin (ThT) binding assays
[25]. These results are shown in Fig. 2A–C. Fig. 2A shows that full-
length hIAPP forms ﬁbrils within 1 day of incubation in buffer. The
ﬁbrils exhibited the typical morphology of amyloid ﬁbrils with widths
between 10 and 15 nm. For hIAPP1–19 at the same concentration, even
after 4 days of incubation, only a few ﬁbrils were observed (Fig. 2B).
The population of hIAPP1–19 ﬁbrillar assemblies consisted of thin
ﬁbrils with a width of 6–10 nm that, contrary to full-length hIAPP, do
not appear to have a strong propensity to cluster. As shown in Fig. 2C,
analysis of the kinetics of ﬁbril formation in the absence of vesicles
yields an S-shaped curve for full-length hIAPP, which is a well-known
characteristic of hIAPP ﬁbril formation [26]. In contrast, the data do
not show any increase in time in ﬂuorescence for hIAPP1–19,
supporting the notion that hIAPP1–19 is only weakly ﬁbrillogenic.
The same experiments were carried out in the presence of vesicles
composed of POPC/POPS in a molar ratio of 7:3 (Fig. 2D–F). Full-length
hIAPP forms ﬁbrils within a day of incubation, with a similar ﬁbril
morphology as in the absence of membranes (Fig. 2D), whereas even
after 15 days of incubationwith POPC/POPS vesicles, hIAPP1–19 does not
form ﬁbrils (Fig. 2E). The ThT assays are in agreement with the TEM
results, as they conﬁrmed the absence of hIAPP1–19 ﬁbrils after 12 days
(Fig. 2F). For full-length hIAPP, the ThT assays show an increase in
ﬂuorescence related toﬁbril formation and an S-shaped curve, as shown
previously. Qualitatively similar results were observed with LUVs
composed of only POPC or only POPS (data not shown). These results
demonstrate that hIAPP1–19 is weakly ﬁbrillogenic in solution and not
ﬁbrillogenic in the presence of membranes, suggesting that in this case,
contrary to full-length peptide, the membranes in fact inhibit ﬁbril
formation.
3.2. hIAPP1–19 does not induce membrane leakage under physiological
membrane compositions
Next, membrane leakage experiments were performed under the
same conditions as used for ﬁbril formation. Membrane damage was
assayed quantitatively by analyzing the extent of leakage of a
ﬂuorescent dye (calcein) from LUVs. As shown in Fig. 3A, full-length
hIAPP induces signiﬁcant leakage in POPC/POPS LUVs to about 80% of
the total vesicle content. The process of leakage is characterized by an
S-shaped curve with a lag time of approximately 2 h. In contrast to
full-length hIAPP, hIAPP1–19 is not able to induce signiﬁcant
membrane damage (only b5% leakage) using the same experimental
conditions. With POPC LUVs, a qualitatively similar result is observed;
an S-shaped curve is obtained for full-length hIAPP, but now with a
smaller extent of leakage (∼25%) and a longer lag time of
approximately 8 h (Fig. 3B), while hIAPP1–19 does not signiﬁcantly
affect barrier properties of the membrane (b5% leakage). In the
presence of POPS LUVs different results are obtained: both peptides,Fig. 1. The amino acid sequence of full-length hIAPP and hIAPP1–19. Both peptides have
an intramolecular disulﬁde bridge and an amidated C-terminus.full-length hIAPP and hIAPP1–19, induce considerable leakage during
the ﬁrst hours and then a plateau is reached (Fig. 3C). Importantly, a
lag phase is not observed in this system, and the leakage increases
exponentially from the start of the incubation. In addition, we should
note that in none of our experiments we reached the maximum value
of 100% leakage. The reason is that the plateau value for leakage
depends on the peptide concentration and on the lipid:peptide ratio.
We have used a peptide concentration of 5 μM and a lipid:peptide
ratio of 9:1, similar to our previous studies [14,20], but not sufﬁcient
to reach 100% leakage. As has been published, a high peptide
concentration of 50 μM hIAPP1-37 combined with a low lipid:peptide
ratio of 4:1 is required to obtain 100% leakage [27].
3.3. Like hIAPP1-37, hIAPP1–19 adopts an α-helical conformation in the
presence of negatively charged lipids
We used CD spectroscopy to investigate the secondary structure of
full-length hIAPP and hIAPP1–19 in the absence and presence of
membranes at the start of the incubation. The CD spectra of full-length
hIAPP and of hIAPP1–19 freshly dissolved in 10 mM phosphate buffer at
25 μM are nearly identical, displaying a peak with negative ellipticity at
200 nm that is characteristic of a random coil conformation (Fig. 4A).
Even at a high peptide concentration of 50 μM, hIAPP1–19 is unstruc-
tured, whereas at this concentration hIAPP1-37 starts showing β-sheet
structure (results not shown). This is in agreement with the lower
amyloidogenic potential of hIAPP1–19, as observed by EM (Fig. 2).
The same experiments were conducted in the presence of
membranes. At these short incubation times, full-length hIAPP adopts
a mixture of mostly α-helical and random coil structure in the
presence of all lipids, but with the highest α-helical content in PS
(Fig. 4B). In the presence of negatively charged lipid (POPC/POPS
mixtures and POPS), the spectrum of hIAPP1–19 displays negative
ellipticity at 208 and 222 nm, characteristic of an α-helical backbone
structure (Fig. 4C). However, without negatively charged lipids (POPC
only), hIAPP1–19 shows a spectrum indicative of random coil
conformation (Fig. 4C), similar to that of hIAPP1–19 in solution.
3.4. hIAPP1–19 retains its initial conformation upon incubation with lipid
membranes, while full-length hIAPP undergoes a conformational
rearrangement
To investigate the relationship between ﬁbril formation and
membrane leakage by full-length hIAPP and hIAPP1–19, we performed
CD measurements to analyse the conformational changes of the
peptides after a few hours of incubation in the presence of membranes.
Fig. 5 shows that in the presence of POPC/POPS or POPC, while full-
length hIAPP adopts a β-sheet structure, hIAPP1–19 retains respectively
its α-helical conformation and its random coil conﬁguration during at
least 2 h. In the presence of POPS both peptides retain an α-helical
structure for few hours (Fig. 5). The α-helical structure of hIAPP1–19
persisted even after 1 day (not shown). These results provide evidence
that PS-containing membranes promote an α-helical conformation in
membrane-bound hIAPP. In addition, in the presence of the tested lipid
membranes, hIAPP1–19 does not change its conformation in time.
4. Discussion
Recent studies have shown that the ability of amyloidogenic
peptides to induce disruption of lipid bilayers is correlated with the
toxicity of such peptides [8,28–30]. Studies on model membranes have
shown that membrane permeabilization by amyloidogenic peptides is
highly dependent on the lipid composition of the membrane [7,11].
Therefore, an understanding of lipid speciﬁcity of amyloid peptide-lipid
interactions can lead to a better understanding of the mechanism of
amyloid cytotoxicity. In the present study we have investigated and
compared the aggregational behaviour in relation tomembranedamage
Fig. 2. Negatively stained electron microscopy images of full-length hIAPP and hIAPP1–19 at 5 μM. (A) Full-length hIAPP after 1 day of incubation in solution and (D) in presence of
POPC/POPS LUVs. (B) hIAPP1–19 after 4 days of incubation in solution and (E) after 15 days of incubation in the presence of POPC/POPS LUVs. Scale bars are 500 nm except in
(E) where it is 100 nm. ThT ﬂuorescence of ﬁbril formation of full-length hIAPP (solid with open squares) and hIAPP1–19 (dashed with ﬁlled circles) at 5 μM. (C) Fibril formation in
solution and (F) in the presence of POPC/POPS LUVs (peptide:lipid ratio 1:9).
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composition (PC only, PS only and a mixture of PC/PS). We have made
the following key observations: i) hIAPP1–19 does not form ﬁbrils in the
presence of membranes of varying lipid composition as used in this
study, whereas full-length hIAPP does, ii) hIAPP1–19 does not induce
leakage of membranes without or with a limited content of anionic
lipids (PC or PC/PS 7/3), whereas again full-length hIAPP does, iii)
hIAPP1–19 does induce leakage in membranes composed of anionic
lipids (PS) only, but this is not accompanied by ﬁbril formation, and iv)
hIAPP1–19 has a conformation that remains stable for several days upon
incubation with LUVs of varying lipid composition. These ﬁndings are
discussed below, together with potential implications for islet amyloid
formation and for the cytotoxic mechanism of action of hIAPP.The EM, CD and ThT ﬂuorescence studies of hIAPP1–19 reveal
several interesting features. The EM results suggest that in solution
this peptide is markedly less ﬁbrillogenic than full-length hIAPP. Only
a few ﬁbrils of hIAPP1–19 were found in different samples after several
days of incubation. These results are consistent with our ThT
ﬂuorescence and CD data that show no increase in ThT signal after a
few days of incubation, and predominantly random coil structure for
hIAPP1–19, even at high peptide concentrations. In the presence of
different membranes (POPC, POPS and POPC/POPS) our EM experi-
ments did not show any evidence at all of ﬁbril formation for hIAPP1–19,
even after 15 days of incubation. In addition, the ThT ﬂuorescence did
not increase during longer incubation times and CD spectroscopy
indicated the absence of β-sheet structure. Hence, these experiments
Fig. 3. Kinetics of membrane permeabilization induced by 5 μM full-length hIAPP (solid with open squares) and 5 μMhIAPP1–19 (dashed with ﬁlled circles). The peptides were added
to calcein containing POPC/POPS (7:3) LUVs (left), POPC LUVs (middle), and POPS LUVs (right) at t=0 (peptide:lipid ratio 1:20). Leakage shown after 1 day is the average of three
experiments with three different peptide stock solutions, of which each experiment was performed in triplicate. The maximum leakage, after complete disruption of all vesicles by
Triton, was set at 1.
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Our result is consistent with the recent notion, based on simulation
studies, that highly ﬁbrillogenic peptides form ﬁbrils more rapidly in
the presence of lipid vesicles than in their absence, whereas the
opposite is observed for peptides of low ﬁbrillogenicity, where ﬁbril
formation is slower in the presence of lipid vesicles [15].
Upon initial interaction with membranes, full-length hIAPP adopts
an α-helical structure. A transition of α-helical to β-sheet structure is
observed in membranes without or with limited content of anionic
lipid (PC and PC/PS). This transition results in ﬁbril formation that is
correlated to membrane damage. This transition has been observed
for many amyloidogenic proteins. Indeed, the Aβ peptide (aggregat-
ing in Alzheimer's disease) and the N-terminal part of α-synuclein
(aggregating in Parkinson's disease) adopt an α-helical structure
before transformation to β-sheet structure [31,32]. For hIAPP1–19, a
different behaviour was observed: the structure of the peptide is
stable in time (random coil in PC and α-helical in PC/PS membranes,
respectively) and no transition to β-sheet structure occurs. In
addition, this peptide does not form ﬁbrils and does not induce
membrane leakage of PC and PC/PS membranes. In membranes
composed of anionic lipids (PS) only, both peptides adopt anα-helical
structure that is stable for a few hours and this is associated with
membrane damage. Hence, both peptides seem to induce membrane
damage that is not correlated to ﬁbril formation. This notion is furtherFig. 4. (A) CD spectra at 25 μM concentrations of hIAPP1–19 (squares) and full-length hIAPP (
full-length hIAPP (B) and of hIAPP1–19 (C) in the presence of POPC LUVs (triangles), POPC/supported by the absence of a lag phase in kinetic experiments, as
explained in the next paragraph.
Previously, for full-length hIAPP a correlation was found between
ﬁbril formation and peptide-induced membrane damage [14]. By
studying the kinetics of hIAPP-induced membrane damage in relation
to hIAPP ﬁbril growth, it was found that the kinetic proﬁle of hIAPP-
induced membrane damage is characterized by a lag phase and a
sigmoidal transition, which matches the kinetic proﬁle of hIAPP ﬁbril
growth. Moreover, it was found that pre-formed ﬁbrils do not induce
membrane damage. It was thus postulated that growth of hIAPP ﬁbrils
at the membrane surface causes hIAPP-induced membrane damage
[14], in agreement with simulation experiments [15]. Our present
data show that hIAPP1–19, although being implicated in membrane
insertion of hIAPP, is not able to form ﬁbrils in the presence of
membranes and, as expected, does not induce leakage of membranes
composed of PC or PC/PS 7/3. These results are thus consistent with
the hypothesis that under physiological conditions, the processes of
ﬁbril formation and membrane damage are causally related [14]. On
the other hand, in POPS LUVs both hIAPP1–19 and full-length hIAPP
induce leakage that is characterized by an immediate, exponential
increase without a lag phase. Importantly, CD data show that under
these conditions both peptides remain helical for few hours,
indicating that the observed leakage is not related to β-sheet
formation that is characteristic of amyloid ﬁbrils. Similar resultsdiamonds) in 10 mM phosphate buffer (pH 7.4). CD spectra at 50 μM concentrations of
POPS 7:3 LUVs (squares) and POPS LUVs (circles) (peptide:lipid ratio 1:20).
Fig. 5. Calculated secondary structure contents of 50 μM hIAPP1–19 and 50 μM full-
length hIAPP in the presence of POPC/POPS LUVs (top), POPC LUVs (middle) and POPS
LUVs (bottom) obtained immediately after the addition of the LUVs and after 120 min
of incubation with the LUVs (peptide:lipid ratio 1:20). Deconvolution of CD spectra was
accomplished using the CDFriend software (see Materials and methods).
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full-length hIAPP and hIAPP1–19 induce membrane disruption in
anionic lipid vesicles and favor the formation of negative curvature,
indicating that these peptides may induce the formation of pores by
the induction of excessmembrane curvature [12,33]. Our results show
that both peptides, full-length hIAPP1-37 and hIAPP1–19, insert into
anionic membranes with an α-helical structure, suggesting that they
could damage the membrane via another mechanism, possibly a
carpet type as reported for antimicrobial peptides [34].
In conclusion, our data suggest that in membranes without or with
a limited content of anionic lipids (PC or PC/PS 7/3) the N-terminal
part of hIAPP is not involved in ﬁbril formation, nor in ﬁbril growth
mediated membrane leakage. However, in anionic lipid (PS) mem-
branes, both full-length hIAPP1-37 and hIAPP1–19 induce membrane
damage that is not correlated to ﬁbril formation. The different
behaviour of the peptides in the presence of membranes composed
of negatively charged lipids may be related to a strong tendency for a
ﬁbril formation inhibiting, parallel orientation of the α-helical 1–19
fragment at the membrane [35]. The different results found in theliterature are most likely due to the lipid membrane composition. We
should note that the use of an ‘extreme’ system such as membranes
composed for 100% of anionic lipid could provide information which
helps to understand peptide/lipid interactions and the role of
electrostatic interactions. However, it does not reﬂect peptide
behaviour in physiologically relevant conditions.
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